A GUIDE TO

deprescribing

phn TASMANIA
An Australian Government Initiative

primary health TASMANIA

CPS Experts in Medicines
CONSULTANT PHARMACY SERVICES

GLAUCOMA EYE DROPS

KEY POINTS

- **Patients who are on topical medications for mild glaucoma or ocular hypertension would be at minimal risk if they were to go off their medications (assuming a life expectancy of 2 years or less). Glaucoma treatment is considered lifelong and the treating ophthalmologist should be actively consulted in the process of considering deprescribing of glaucoma treatment.**
- **Consider discontinuation in patients who have significant difficulty with medication administration and whose life expectancy may be limited.**
- **Patients with advanced glaucoma are likely to lose vision over time if medications are ceased.**
- **Symptomatic vision loss from glaucoma indicates that glaucoma is advanced, and that medications should be continued.**

FOR BETTER HEALTH OUTCOMES

CONTEXT

This guide considers the use of topical ophthalmic agents for open-angle glaucoma, particularly in patients with a limited life expectancy and those with difficulties relating to administration of eye drops.

RECOMMENDED DEPRESCRIBING STRATEGY

- Review of glaucoma medications should be considered when the patient has a short life expectancy, and/or is having problems or difficulties with their medications.
- The IOP will increase after treatment cessation – the impact that this will have on the patient's vision depends stage of the disease, the extent of pressure elevation and the rate and location of visual field loss and their life expectancy. Patients who are on topical medications for mild glaucoma or ocular hypertension would be at minimal risk if they were to go off their medications (assuming a life expectancy of 2 years or less). Patients with advanced glaucoma, are at substantially higher risk of vision loss after medication cessation.

DEPRESCRIBING ALGORITHM



BENEFIT VERSUS HARM

Favours Continuing Medication | **Favours Deprescribing Medication**

Main Benefits
- Reduced intraocular pressure and slowing of vision loss

Main Harms
- Mostly well tolerated

Increased Benefit
- More advanced glaucoma with symptomatic vision loss
- Markedly elevated intraocular pressure (>35mmHg)

Reduced Harms
- Correct administration technique

Decreased Benefits
- Mild galucoma
- Difficulty with administration
- Limited life expectancy

Increased Harms
- Systemic effects from lack of punctual occlusion with administration

BACKGROUND

Glaucoma is the most common neurodegenerative disease of the optic nerve, with a prevalence of about 3%.[1] This means that about 150,000 Australians, about 75% of whom are aged over 70, have glaucoma. This number will double over the next 30 years as our population ages.[2] Glaucoma is often referred to as the "silent thief of sight" as vision loss may progress gradually without the patient noticing.

The glaucomas are characterised by optic neuropathy, optic disc changes and progressive visual field loss caused by the degeneration of retinal ganglion cells. Degeneration results in "cupping" or excavation of the optic disc and vision loss.3 Increased intraocular pressure (IOP) or "ocular hypertension" is the only modifiable risk factor for glaucoma.

Although the pathogenesis of glaucoma is not fully understood, the level of intraocular pressure is related to retinal ganglion cell death. The balance between secretion of aqueous humor by the ciliary body and its drainage through 2 independent pathways – the trabecular meshwork and uveoscleral outflow pathway – determines the IOP. In patients with open-angle glaucoma, there is increased resistance to aqueous outflow through the trabecular meshwork. In contrast, the access to the drainage pathways is obstructed typically by the iris in patients with angle-closure glaucoma (**Figure 1**).



Figure 1: Aqueous humor drainage pathways of healthy and glaucomatous eyes.[3]

Although elevated IOP is a risk factor for glaucoma, a significant proportion of people with glaucoma have IOPs that are not elevated and some people with elevated IOP may never develop glaucoma.[3] The presence of characteristic visual field defects can confirm the diagnosis, but as many as 30-50% of retinal ganglion cells may be lost before defects are detectable by standard visual field testing.[3]

TARGET IOPs[4]

A target IOP for treatment is determined based upon the patient's risk factors for glaucoma progression, the extent of optic nerve damage, rate of deterioration, risk factors for progression, life expectancy, and potential for adverse effects from treatment. In general, the initial target aims for 20% to 50% reduction in the IOP; however, the target pressure needs to be continuously reassessed during patient follow-up, depending on the evolution of the disease. The maintenance of IOPs in the low to mid teens (<15 mmHg) may be the goal for advanced primary open angle glaucoma.

RISK FACTORS

The risk of glaucoma is highest when examination reveals an increased cup-disk ratio (CDR), CDR asymmetry, disc haemorrhage, or elevated intraocular pressure. Factors that predispose to glaucoma that may warrant referral to a optometrist or ophthalmologist include: [3]

- Older age
- Family history of glaucoma
- Black race
- Use of systemic or topical corticosteroids

EFFICACY

Topical drugs are first-line treatment (either alone or in combination). They reduce IOP by decreasing production of aqueous humor and/or by increasing its outflow. The ultimate objective of glaucoma treatments is to preserve the remaining visual field (i.e., to stop visual field defect progression).

The Ocular Hypertension Treatment Study randomized patients with ocular hypertension (high IOP but no clinical signs of glaucomatous damage to the optic nerve or visual field) to treatment vs no treatment. At the end of 5 years of follow-up, 4.4% of patients in the medication group vs 9.5% in the untreated group developed signs of glaucoma.[5] The Early Manifest Glaucoma Trial also randomized patients to treatment vs no treatment; with all patients having a clear diagnosis of glaucoma at the baseline visit. After a median follow-up of 6 years, progression was less frequent in the treatment group (45%) than in the control group (62%).[6]

This highlights that progression can be slow for some individuals and that review of medication treatment is appropriate in individuals whose life expectancy might be limited, or in whom adverse effects of difficulty with medication administration may be a problem.

The target IOP should be achieved with the fewest medications and minimum adverse effects. Several different classes of pressure-lowering medications are available (**Table 1**). Medication choice may be influenced by cost, adverse effects, and dosing schedules. In general, prostaglandin analogues are the first line of pharmacological therapy. These drugs reduce IOP by reducing outflow resistance resulting in increased aqueous humor flow through the uveoscleral pathway.

Other classes of topical medications are less effective in lowering IOP than prostaglandin analogues. They are used as second-line agents or when there is a contraindication or intolerance to the use of prostaglandin analogues. Laser treatment may reduce or delay the need for topical therapy in some patients and surgical interventions are considered if drug treatment is inadequate or intolerable.

Please refer to **Table 1** on page 4 for more information about topical medications for glaucoma.

ADVERSE EFFECTS

The prostaglandin analogues are administered once nightly and generally have few systemic adverse effects. However, they can cause local adverse effects such as conjunctival hyperemia, elongation and darkening of eyelashes, loss of orbital fat (so-called prostaglandin-associated periorbitopathy), induced iris darkening, and periocular skin pigmentation. They often exacerbate dry eye, ocular surface disease and blepharitis which can be a common ocular comorbidity. Some of the other agents, such as adrenergic blockers, may have significant systemic adverse effects and can be contraindicated in patients with history of significant chronic pulmonary obstructive disease, asthma, or bradycardia.

Eye drops contain main therapeutic agents, along with various additives, including preservatives. It is worth noting that, as opposed to benzalkonium, purite and polyquad preservative are considered gentler. Most preservatives also act as surfactants which destabilize bacterial cell membranes. This causes destruction of the cell membrane, inhibition of cell growth, and reduction of cell adhesiveness. However, preservatives also exert these effects on normal corneal and conjunctival cells, resulting in ocular surface disorders. These include superficial punctate keratitis, corneal erosion, conjunctival allergy, conjunctival injection, and anterior chamber inflammation.[7]

Correct instillation technique has been identified as a problem for patients using glaucoma medications. Many patients do not wait a sufficient time between instilling multiple ocular agents, with approximately 5 minutes considered necessary. In the case of uncertainty as to whether an eye drop has been correctly applied it is generally recommended that a second drop is instilled. Punctal occlusion following eye drop administration may reduce systemic effects. Non-compliance and intermittent compliance with treatment is very common."

DRUG CLASS	MECHANISM OF ACTION/ DOSING	OPHTHALMIC SIDE EFFECTS	SYSTEMIC SIDE EFFECTS
prostaglandin analogues (bimatoprost, latanoprost, tafluprost, travoprost)	▪ once daily at night, though can be used in the morning but are less effective (less effective if given more than once daily) ▪ increase in uveoscleral outflow of aqueous humor ▪ first line therapy – the most effective class of medications	▪ conjunctival hyperaemia (less with latanoprost) ▪ lengthening and darkening of eyelashes ▪ brown discoloration of the iris ▪ exacerbation of dry eye and blepharitis ▪ uveitis ▪ macular oedema ▪ orbital fat atrophy ▪ periocular skin pigmentation ▪ blurred vision ▪ burning, stinging ▪ foreign body sensation	▪ unlikely
beta-blockers (betaxolol, timolol)	▪ 1-2 times daily ▪ reduction of aqueous humor production	▪ burning & stinging ▪ photophobia ▪ itching ▪ tearing ▪ decreased corneal sensitivity ▪ hyperaemia ▪ diplopia	▪ bronchospasm ▪ hypotension ▪ bradycardia ▪ heart block ▪ mask hypoglycaemia ▪ impotence ▪ fatigue ▪ depression ▪ alopecia ▪ confusion
alpha2 agonists (apraclonidine, brimonidine)	▪ 2-3 times daily ▪ initial reduction of aqueous humor production with subsequent effect of increase in outflow ▪ second line treatment ▪ tachyphylaxis can develop	▪ allergic reaction is relatively common ▪ ocular irritation ▪ dry eyes ▪ foreign-body sensation ▪ hyperaemia ▪ lid retraction ▪ conjunctival blanching ▪ photophobia	▪ dry mouth ▪ headache ▪ fatigue ▪ drowsiness ▪ bradycardia ▪ hypotension ▪ apnoea ▪ taste disturbance ▪ syncope
carbonic anhydrase inhibitors (brinzolamide, dorzolamide, acetazolamide)	▪ 2-3 times daily ▪ reduction of aqueous humor production ▪ second line treatment ▪ acetazolamide used in more acute and serious glaucoma	▪ burning & stinging ▪ itching ▪ blepharoconjunctivitis ▪ dry eyes	▪ bitter taste ▪ headache ▪ nausea ▪ fatigue ▪ dry mouth ▪ dizziness ▪ anaphylaxis
cholinergic (pilocarpine)	▪ 3-4 times daily ▪ increase in aqueous humor outflow	▪ eye pain ▪ decrease in night vision ▪ blurred vision ▪ myopic shift ▪ miosis ▪ retinal detachment ▪ lacrimation	▪ headache ▪ salivation ▪ urinary frequency ▪ diarrhoea ▪ abdominal cramps ▪ bronchospasm ▪ hypotension ▪ bradycardia ▪ nausea & vomiting

Table 1; Topical ophthalmic medications for glaucoma

FACTORS TO CONSIDER

IN FAVOUR OF DEPRESCRIBING

The stage of disease can be graded considering the amount of disc damage. The optic discs may be graded in three zones: green, yellow or red. In the green zone, the patients do not have definite damage. When a patient is in the yellow zone, the optic nerve is damaged, but the person may still be asymptomatic. Finally, when a person is already in the red zone, there is already moderate to advanced damage and the person has visual disability. The patient may have decreased quality of life or impaired ability to perform daily activities.[9] Review of medication treatment may be appropriate in individuals whose life expectancy might be limited, or in whom adverse effects or difficulty with medication administration may be a problem.

CHALLENGES IN PREDICTING PROGRESSION OF VISUAL FIELD LOSS [10]

- The predictive value of IOP in determining whether the optic disc and/or visual field will deteriorate is almost non-existent unless the IOP is in a range which is always abnormal, that is above 35mmHg.[11]
- There is virtually no predictive value of an individual's IOP in determining who will become visually disabled;
- It is possible to slow the rate of visual field loss in patients with glaucoma, yet many patients with glaucoma still experience visual field loss despite treatment;
- Performance on visual field testing can be unreliable. Reliability often increases with repeat testing over time.
- The significance of glaucoma is a function of the severity of the disease, the duration of the disease and the rate of progression

Given the complexity of the issues noted above, the involvement of the patients ophthalmologist is strongly recommended when considering deprescribing topical ophthalmic agents for glaucoma.



Figure 2: Glaucoma Colour Graph 'The Glaucoma Process'

AGAINST DEPRESCRIBING

Generally, glaucoma treatment is considered to be life-long unless there are changes to an individual's circumstances that prompt a review. Evidence indicates that factors associated with greater risk of glaucoma progression include:[12]

- Elevated/ fluctuating IOP
- Optic disc haemorrhage
- An increased CDR or CDR asymmetry
- Increased severity of glaucomatous disc damage and
- Very low blood pressure.

These patients usually require greater reduction in IOP. An NHMRC review of the diagnosis and management of glaucoma concluded, "There is a paucity of information regarding the management of glaucoma in elderly patients such as those in nursing homes and aged care facilities. For example, beta-blockers have been shown to increase the risk of falls in the elderly, more research may be available to inform subsequent revisions of this guideline." [4]

FACTORS AGAINST DEPRESCRIBING GLAUCOMA MEDICATION:

- advanced disc cupping as documented by ophthalmologist
- advanced visual field loss (MD on humphrey static perimetry less than or equal to -15 dB)
- visual field defect involving the central part of the vision in one or both eyes
- loss of vision in one eye from glaucoma already
- known very high pre-treatment IOP (over 35mmHg)
- glaucoma medications should be continued where a person continues to:
  - be able to read
  - use their vision to perform tasks that improve their quality of life
  - be able to articulate visual symptoms
  - attend for ophthalmic investigations and examinations despite entrance into settings such as residential care.
- loss of peripheral visual field from glaucoma can increase the risk of falls and this is a major cause of morbidity in older patients.

RESOURCES

- GENERAL INFORMATION
- ALLOPURINOL
- ANTIHYPERGLYCAEMICS
- ANTIHYPERTENSIVES
- ANTIPSYCHOTICS
- ASPIRIN
- BENZODIAZEPINES
- BISPHOSPHONATES
- CHOLINESTERASE INHIBITORS
- GLAUCOMA EYE DROPS
- NSAIDS
- OPIOIDS
- PROTON PUMP INHIBITORS
- STATINS
- VITAMIN D AND CALCIUM

AUTHORSHIP

This guide was prepared by Dr Shane Jackson, Dr Mark Naunton and Dr David Wechsler.

MAY 2019

DISCONTINUATION SYNDROMES

The increase in IOP that follows discontinuation of topical hypotensive agents in primary open angle glaucoma is asymptomatic however the patient may experience visual field loss if the glaucoma is advanced. Change is vision is often insidious until the most advanced stages, meaning that progression may go unnoticed by the patient. Furthermore patients who are unwell or who have multiple medical comorbidities may have difficulty noticing or communicating changes in their vision.

REFERENCES

1. Mitchell P, Smith W, Attebo K, Healey P. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. Ophthalmology. 1996;103:1661-9.
2. Rochtchina E, Mitchell P. Projected number of Australians with glaucoma in 2000 and 2030. Clin Exp Ophthalmol 2000;28:146-8.
3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014;311(18):1901-11.
4. Council) NNHaMR. NHMRC Guidelines for the screening prognosis diagnosis management and prevention of glaucoma 2010.
5. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of ophthalmology. 2002;120(6):701-13; discussion 829-30.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology. 2002;120(10):1268-79.
7. Inoue K. Managing adverse effects of glaucoma medications. Clinical ophthalmology. 2014;8:903-13.
8. 8.Kass M, Hodapp E, Gordon M, Kolker A, Goldberg I. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol. 1982;14(8):775-9.
9. Spaeth, Paulus. The colored glaucoma graph and its use in caring for patients with glaucoma: a new system of management presented in three parts. J Curr Glaucoma Pract. 2010;4:83-90.
10. Zangalli C, Gupta SR, Spaeth GL. The disc as the basis of treatment for glaucoma. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2011;25(4):381-7.
11. Foster PJ, Machin D, Wong TY, Ng TP, Kirwan JF, Johnson GJ, et al Determinants of intraocular pressure and its association with glaucomatous optic neuropathy in Chinese Singaporeans: the Tanjong Pagar Study. Investigative ophthalmology & visual science. 2003;44(9):3885-91.
12. Hollands H, Johnson D, Hollands S, Simel DL, Jinapriya D, Sharma S. Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. Jama. 2013;309(19):2035-42.

Experts in Medicines
CONSULTANT PHARMACY SERVICES
www.consultantpharmacyservices.com.au

phn TASMANIA
An Australian Government Initiative
primary health TASMANIA
www.primaryhealthtas.com.au